Credit: Shutterstock photoInvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Sarepta Therapeutics Inc ( SRPT ) stock was up after the company announced a delay from the U.S. Food and Drug Administration (FDA).
Serapta announced that the FDA will continue to review the drug past the PDUFA date and that it hopes to finish its work in a timely manner. SRPT is a company that has a focus on developing RNA-targeted therapeutics.
The decision by the FDA to delay its review could be a positive sign for Sarepta . The company's future is riding on the agency's ruling and the delay could be a sign that the drug is closer to approval.
SRPT shares were up 17% as of Noon Wednesday.
More From InvestorPlace:
- The 10 Best Healthcare Stocks to Buy Now
- The Top 10 S&P 500 Dividend Stocks to Buy Now
- The 10 Best Index Funds to Buy Right Now
The post Sarepta Therapeutics Inc (SRPT) Stock Surges as FDA Delays Review of Key Drug appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
